The clinical-stage biopharmaceutical company Aligos Therapeutics, Inc. (Nasdaq:ALGS), which focuses on creating novel treatments for unmet medical needs in viral and liver diseases, announced today that enrollment in a 12-week dosing cohort of HBeAg-positive chronic hepatitis dB (CHB) subjects has started in the ongoing Phase 1b study ALG-000184-201 (NCT04536337). Lawrence Blatt, Ph.D., MBA, CEO, and Chairman of the Board at Aligos(Nasdaq: ALGS), said “This is a critical next step in our consideration of ALG-000184 as a chronic suppressive therapy and/or component of a functional cure regimen in patients with CHB.”
In both HBeAg-negative and -positive CHB individuals, oral ALG-000184 doses up to 100 mg administered daily for 28 days were well tolerated, had outstanding pharmacokinetic features, and may have had best-in-class antiviral efficacy, as we recently reported at the International Liver Congress in London. We may now investigate if longer-term dosing is still well tolerated and whether higher suppression of significant viral parameters, including HBV DNA and RNA, in HBeAg-positive participants, is possible thanks to the start of this 12-week cohort at the 100 mg prescription level. It is well recognized that HBeAg-positive patients have substantially greater baseline HBV DNA and RNA levels than HBeAg-negative patients, making them more difficult to treat.
We anticipate sharing findings from this significant cohort at a scientific conference in Q4 2022, based on the enrolment rate currently in place.
About Aligos(Nasdaq:ALGS)
A clinical-stage biopharmaceutical firm called Aligos Therapeutics, Inc. (Nasdaq:ALGS) was established in 2018 to dominate the global market for the treatment of viral infections and liver conditions. In addition to using its knowledge of liver illnesses to develop tailored medicines for nonalcoholic steatohepatitis, Aligos(Nasdaq:ALGS), is concentrated on the research and development of targeted antiviral medications for chronic hepatitis B (CHB) and coronaviruses (NASH). The goal of Aligos’ strategy is to swiftly advance its pipeline of potentially best-in-class compounds by utilizing the extensive knowledge and decades of drug development experience that its team has in liver disease, particularly viral hepatitis.
Featured Image: DepositPhotos @pressmaster
